Matthay Katherine K, Reynolds C Patrick, Seeger Robert C, Shimada Hiroyuki, Adkins E Stanton, Haas-Kogan Daphne, Gerbing Robert B, London Wendy B, Villablanca Judith G
University of California School of Medicine, 505 Parnassus Ave, Room M647, San Francisco, CA, 94143-0106, USA.
J Clin Oncol. 2009 Mar 1;27(7):1007-13. doi: 10.1200/JCO.2007.13.8925. Epub 2009 Jan 26.
PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation (ABMT) or to receive chemotherapy, and subsequent treatment with 13-cis-retinoic acid (cis-RA). PATIENTS AND METHODS Patients received the same induction chemotherapy, with random assignment (N = 379) to consolidation with myeloablative chemotherapy, total-body irradiation, and ABMT versus three cycles of intensive chemotherapy. Patients who completed consolidation without disease progression were randomly assigned to receive no further therapy or cis-RA for 6 months. Results The event-free survival (EFS) for patients randomly assigned to ABMT was significantly higher than those randomly assigned to chemotherapy; the 5-year EFS (mean +/- SE) was 30% +/- 4% versus 19% +/- 3%, respectively (P = .04). The 5-year EFS (42% +/- 5% v 31% +/- 5%) from the time of second random assignment was higher for cis-RA than for no further therapy, though it was not significant. Overall survival (OS) was significantly higher for each random assignment by a test of the log(-log(.)) transformation of the survival estimates at 5 years (P < .01). The 5-year OS from the second random assignment of patients who underwent both random assignments and who were assigned to ABMT/cis-RA was 59% +/- 8%; for ABMT/no cis-RA, it was 41% +/- 8% [corrected]; for continuing chemotherapy/cis-RA, it was 38% +/- 7%; and for chemotherapy/no cis-RA, it was 36% +/- 7%.
Myeloablative therapy and autologous hematopoietic cell rescue result in significantly better 5-year EFS than nonmyeloablative chemo therapy; neither myeloablative therapy with [corrected] autologous hematopoietic cell rescue nor cis-RA given after consolidation therapy significantly improved OS.
目的 我们评估了参加CCG - 3891研究的高危神经母细胞瘤患者的长期预后。在该研究中,患者被随机分配接受自体净化骨髓移植(ABMT)或接受化疗,随后接受13 - 顺式维甲酸(顺式RA)治疗。患者与方法 患者接受相同的诱导化疗,随机分配(N = 379)接受清髓性化疗、全身照射和ABMT巩固治疗,与接受三个周期的强化化疗。无疾病进展完成巩固治疗的患者被随机分配接受无进一步治疗或接受顺式RA治疗6个月。结果 随机分配接受ABMT的患者的无事件生存期(EFS)显著高于随机分配接受化疗的患者;5年EFS(均值±标准误)分别为30%±4%和19%±3%(P = 0.04)。从第二次随机分配时起,顺式RA组的5年EFS(42%±5%对31%±5%)高于无进一步治疗组,尽管差异无统计学意义。通过对5年生存估计值的对数(-对数(.))转换检验,每次随机分配的总生存期(OS)均显著更高(P < 0.01)。接受两次随机分配且被分配到ABMT/顺式RA的患者从第二次随机分配起的5年OS为59%±8%;ABMT/无顺式RA组为41%±8%[校正后];继续化疗/顺式RA组为38%±7%;化疗/无顺式RA组为36%±7%。
清髓性治疗和自体造血细胞挽救导致5年EFS显著优于非清髓性化疗;巩固治疗后给予清髓性治疗和[校正后]自体造血细胞挽救以及顺式RA均未显著改善OS。